Navigation

Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review): biological agents for metastatic colorectal cancer - electronic audit tool

An electronic audit tool has been developed to support the implementation of this NICE guideline. The aim is to assist organisations with clinical audit, helping to ensure that practice is in line with the NICE recommendations. It is an Excel spreadsheet into which data can be entered and the results will then be generated automatically.

Disclaimer
This resource is an implementation tool and should be used alongside the published guidance. The information does not supersede or replace the guidance itself.

We welcome feedback to help inform the development of future tools. Please email your comments to auditsupport@nice.org.uk

This page was last updated: 02 August 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.